



Investment Research CenterSM
 Provided by Arlington Public Library

Home	Companies	Funds	ETFs	Markets	Articles & Videos	Portfolio	Help & Education	Newsletter
------	-----------	-------	------	---------	-------------------	-----------	------------------	------------

AbbVie Inc ABBV |

Quote	Chart	Stock Analysis	Performance	Key Ratios	Financials	Valuation	Insiders	Shareholders	Transcr
-------	-------	-----------------------	-------------	------------	------------	-----------	----------	--------------	---------

Analyst Research Analyst Report Archive Top Rated Stocks in Sector

AbbVie's outlook depends highly on a well-positioned Humira and late-stage pipeline drugs.



by
 Damien
 Conover
 Sector Director

Authors can be reached at [Analyst Feedback](#)

Morningstar's [Editorial Policies](#)

Analyst Note 07/24/2015

AbbVie reported second-quarter results largely in line with both our and consensus expectations, but some softness in international Humira sales and a slower-than-expected launch with hepatitis C treatment Viekira are concerning. We don't expect any changes to our \$61 fair value estimate or narrow moat rating.

With Humira sales generating more than 60% of total sales in the quarter, long-term Humira sales assumptions are critical to the valuation and competitive advantages of the firm. Despite the slowing international Humira growth in the quarter (up 4% operationally, partly weighed down by order timing), sales in the United States shot up an impressive 29% versus the prior-year period. We expect Humira sales to remain robust until patent expirations between 2016 and 2018. However, we are more concerned than the investment community regarding the threat of biosimilar Humira competition in 2017. By 2020, we estimate Humira sales of \$8 billion (versus consensus of \$13 billion). AbbVie has several strategies to keep biosimilars at bay, including longer-duration (but less powerful) patents, a modified, more powerful formulation, and expanding labeled indications. However, we believe Humira's very high margins and multi-billion-dollar sales are attracting several highly motivated biosimilar entrants (six in Phase III development, including Amgen and Novartis).

Realizing the growing competitive headwinds to Humira, AbbVie is making strong strides to diversify its portfolio. While the quarterly sales of hepatitis C drug Viekira fell 25% short of our expectations in the quarter, we expect the drug to

Morningstar's

Analyst

Price 08-17-2015
 69.37 USD

Consider Buy
 42.7 USD

Stewardship Rating
 Standard

Bulls Say

- AbbVie supports a which should act support the divide
- We believe Humir drugs for RA, Croh will continue to pe
- The new competit likely take much s safety and efficacy requires heavy mc

Bears Say

- Several of AbbVie' other drug compa the new drugs.
- The poor competit mean a slow sales drag on overall co
- Besides the hepat not as strong as tl growth following t

grow rapidly through the end of the year, followed by flat growth as more companies enter the market. Also, AbbVie's recent acquisition of Pharmacyclics brought in fast-growing cancer drug Imbruvica. Lastly, AbbVie's midstage pipeline is very strong, which should offer further protection from the eventual Humira biosimilar competition.

Competitors ABBV

Name

AbbVie Inc

Johnson & Johnson

Novartis AG

Novartis AG ADR

Pfizer Inc

Merck & Co Inc

Investment Thesis 10/31/2014

Armed with a best-in-class immunology drug Humira, AbbVie is well-positioned to drive strong cash flows to support the company's next generation of pipeline drugs. At over 50% of total sales and a higher portion of earnings (due to higher margin revenue), Humira is well positioned to drive the majority of AbbVie's performance over the next three years. With approvals in rheumatoid arthritis, psoriasis, and Crohn's disease, Humira should continue to grow in these markets as penetration rates are below 25% on average. With leading efficacy and a favorable side-effect profile, we expect Humira to continue to post double-digit growth over the next couple of years.

Despite a strong near-term outlook for Humira, uncertainty around encroaching competition will likely weigh on investor sentiment toward the company. In particular, Pfizer's new RA drug, Xeljanz, represents a key new competitor, as it offers similar efficacy and oral dosage (in contrast to twice-monthly Humira injections). Also, while Humira's biologic composition may deter generic completion following the late-2016 patent loss in the U.S. and the 2018 patent loss in Europe, we model in 20% annual revenue declines for Humira by 2019.

Beyond Humira, a combination of products losing patent protection and mature drugs largely represents sales outside of Humira. The company's testosterone drug Androgel will likely face generic competition in 2015. In addition, many of the other remaining products have already lost patent protection, but due to manufacturing complexities have been able to retain a significant portion of sales.

Looking ahead, AbbVie's pipeline is weighted heavily toward 2015 launches, with its hepatitis C drugs representing the crown jewel in the pipeline with upside reaching over \$3 billion annually. We expect this hepatitis C treatment to carry very high margins based on the favorable efficacy data enabling strong pricing power. Further, we expect the 2015 launch year to show a high trajectory of sales growth given the limited treatment options in hepatitis C.

Economic Moat 10/31/2014

We believe AbbVie supports a narrow moat based on patent-protected drugs, intellectual intangibles and a powerful salesforce. As is the case for most drug firms, the core of AbbVie's moat lies in its portfolio of patent-protected drugs. However, unlike AbbVie's Big Pharma peers, which tend to carry wide moats, one drug (Humira) represents the majority of AbbVie's sales (50%) and profits (greater

than 70%). As a result of both emerging branded competition to Humira in the immediate term and a potential generic biosimilar threat in the 2017-18 time frame, we believe excess returns are likely to persist for 10 years, but we cannot be as certain of this for our 20-year outlook, which would be needed for a wide moat rating. Further supporting our narrow moat rating, AbbVie holds a relatively weak pipeline with a high concentration of new drugs in the very competitive hepatitis C market. A stronger pipeline and a more diverse product lineup would be needed for a wide moat rating.

Nevertheless, AbbVie derives enormous cash flows from its current product portfolio to fund ongoing discovery and development of the next generation of drugs. The large cash flows create an economy of scale that enables AbbVie to fund the average \$800 million required for a new drug. While not as strong as other Big Pharma firms, AbbVie's R&D has created a database of intellectual insights that should help increase the odds of successful drug development. Finally, AbbVie's entrenched sales force in one of the most sought-after therapeutic areas of immunology should help the firm launch its next generation of drugs and make the company a leading candidate for smaller drug firms needing help to develop and commercialize innovative new drugs.

Valuation 10/31/2014

We are raising our fair value estimate to \$61 per share from \$54 based on increased sales projections for Humira and higher-margin assumptions for the company's hepatitis C treatment. As the most valuable pipeline assets, the hepatitis C drugs look well-positioned to add to the company's overall growth. Based on the strong launch from Gilead's hepatitis C drug Sovaldi, we expect peak sales for AbbVie hepatitis C drugs to reach \$4.5 billion. However, Humira is still the most important drug for AbbVie. Accounting for more than half of AbbVie's projected 2014 sales, Humira is the key driver of its valuation and outlook. We believe Humira's leading efficacy and relatively clean side-effect profile in underpenetrated treatment areas, including RA, psoriasis, and inflammatory bowel disease, will drive an 13% three-year CAGR for the drug. However, we expect Humira sales will begin to decline approximately 20% by 2019 as generic biologics increase and greater branded competition intensifies, which lowers our 10-year CAGR for the drug to negative 6%. Aside from Humira, AbbVie holds several drugs that are losing patent protection over the next five years, which offsets the near-term Humira growth and results in a total sales five-year CAGR of 7%. On the bottom line, over the next five years we expect improving margins, largely driven by the higher contribution to total sales by Humira and hepatitis C drugs, both of which carry very high margins. For the weighted average cost of capital, we use an 8% rate that combines a 8% cost of equity and market rates for the cost of debt.

Risk 10/31/2014

Similar to other drug companies, AbbVie faces the risks of new product failures, reimbursement challenges for new drugs, and drug pricing cuts by large payer groups that are growing increasingly price-sensitive. Further, AbbVie's high concentration of Humira sales makes the company very exposed to any new competitive threats to Humira. Key emerging competitive threats to Humira include Pfizer's oral RA drug Xeljanz, cheaper generic versions of Remicade in Europe, and several other Phase III drugs that hold very strong efficacy or more convenient dosing than Humira.

Management 10/31/2014

We believe AbbVie's management team has demonstrated Standard stewardship, as the key leaders haven't had much of a track record yet. While the failed acquisition attempt for Shire is concerning, we believe the new abrupt U.S. Treasury laws largely caused the acquisition to collapse, somewhat giving management a pass. Nevertheless, the \$1.6 billion breakup fee related to the failed Shire deal does show that management didn't gauge the political landscape correctly.

Turning to management specifically, AbbVie is led by Rick Gonzalez, who joined Abbott in 1977 and held many managerial posts throughout his career there. However, he only recently led the drug group starting in July 2010 after a brief retirement. His relatively short tenure in the key field of drug commercialization and development is a concern, but execution has been going well under his leadership. Backing up Gonzalez, CFO Bill Chase has been with Abbott for more than 20 years. Chase's background in licensing and acquisitions will be helpful, as AbbVie will need to redeploy the strong cash flows from Humira into acquisitions and partnering to augment the company's light pipeline.

Overview

Profile:

AbbVie is a pharmaceutical company with a strong exposure to immunology and virology diseases. The company's top drug, Humira, represents over half of the firm's profits. The company was spun off from Abbott in early 2013.

S&P 500 index data: S&P 500 Copyright @ 2015

All data from Morningstar except U.S. intraday real-time exchange quotes, which are provided by BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. @ Copyright 2015 Morningstar, Inc.

Contact us. Please read our User's Agreement and Troubleshooting documents.
©2015 Morningstar, Inc. All rights reserved.